Lantern Pharma Inc.
LTRN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $4 | $0 | $0 | $51 |
| Gross Profit | -$4 | $0 | $0 | -$51 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,437 | $3,068 | $3,264 | $4,270 |
| G&A Expenses | $0 | $1,526 | $1,452 | $0 |
| SG&A Expenses | $1,909 | $1,584 | $1,510 | $1,576 |
| Sales & Mktg Exp. | $0 | $58 | $58 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $4,346 | $4,652 | $4,774 | $5,845 |
| Operating Income | -$4,350 | -$4,652 | -$4,774 | -$5,896 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $172 | $321 | $237 | $21 |
| Pre-Tax Income | -$4,177 | -$4,331 | -$4,537 | -$5,875 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,177 | -$4,331 | -$4,537 | -$5,875 |
| % Margin | – | – | – | – |
| EPS | -0.39 | -0.4 | -0.42 | -0.54 |
| % Growth | 2.5% | 4.8% | 22.2% | – |
| EPS Diluted | -0.39 | -0.4 | -0.42 | -0.54 |
| Weighted Avg Shares Out | 10,833 | 10,785 | 10,785 | 10,785 |
| Weighted Avg Shares Out Dil | 10,833 | 10,785 | 10,785 | 10,785 |
| Supplemental Information | – | – | – | – |
| Interest Income | $101 | $115 | $150 | $161 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4 | $5 | $5 | $51 |
| EBITDA | -$4,173 | -$4,647 | -$4,769 | -$5,824 |
| % Margin | – | – | – | – |